and for pesticides with import tolerances only.

iii. *Registration*. Like older pesticides, all new pesticide registrations must meet the safety standard of FFDCA. Many of the registration applications EPA receives are for new uses of pesticides already registered for other uses. To reach a decision on a proposed new food use of an already registered pesticide, EPA must reassess the aggregate risk of the the existing tolerances, as well as the proposed new tolerances, to make sure there is reasonable certainty that no harm will result to the public from aggregate exposure from all uses.

iv. *Tolerance revocations*. When EPA has canceled use on a particular crop or commodity of all products containing a pesticide active ingredient, the Agency ordinarily will revoke the tolerance, unless a party provides data to support it as an import tolerance. Some pesticides were canceled due to the Agency's risk concerns. Others were canceled voluntarily by their manufacturers, based on economic decisions not to support reregistration. Tolerance revocations are important even if there are no domestic uses of a pesticide because residues in or on imported commodities treated with the chemical could still present dietary risks that may exceed the FFDCA ''reasonable certainty of no harm'' standard, either individually or cumulatively with other substances that share a common mechanism of toxicity.

v. *Other reassessment decisions*. In addition to the types of reassessment actions described above, a total of 1,605 additional tolerance reassessment decisions were made. Some were made for inert ingredient tolerance exemptions through actions not directly related to registration or reregistration.

2. *Accomplishments for priority pesticides*. During FY 2007, EPA completed the remaining 84 tolerance reassessment decisions for the high priority N-methyl carbamate pesticides. This completes the reassessment of priority pesticides.

F. Applications for Registration Requiring Expedited Processing; Numbers Approved and Disapproved

By law, EPA must expedite its processing of certain types of applications for pesticide product registration, i.e., applications for end-use products that would be identical or substantially similar to a currently registered product; amendments to current product registrations that do not require review of scientific data; and products for public health pesticide uses. During FY 2007, EPA considered and approved the numbers of applications for registration requiring expedited processing (also known as ''fast track'' applications) shown in Table 6.

TABLE 6.—FAST TRACK APPLICATIONS APPROVED IN FY 2007

Me-too product registrations/Fast track	394
Amendments/Fast track	3,441
Total applications processed by fast track means	3,835

For those applications not approved, the Agency generally notifies the registrant of any deficiencies in the application that need to be corrected or addressed before the application can be approved. Applications may have been withdrawn after discussions with the Agency, but none were formally ''disapproved'' during FY 2007.

On a financial accounting basis, EPA devoted 25.4 full-time equivalents (FTEs) in FY 2007 to reviewing and processing applications for fast track me-too product registrations and label amendments. The Agency spent approximately $3.15 million in FY 2007 in direct costs (i.e., time on task, not including administrative expenses, computer systems, management overhead, and other indirect costs) on expedited processing and reviews.

G. Future Schedule for Reregistrations

EPA plans to complete the remaining 27 REDs in FY 2008, meeting the October 3, 2008 PRIA deadline. The Agency's schedule for completing these decisions is as follows. This schedule also is available on EPA's website at *http://www.epa.gov/pesticides/reregistration/decision_schedule.htm*.

List 1.—FY 2008 REDs Schedule

Acrolein
Busan 77
Chloropicrin
Chromated arsenicals (CCA)
Coal tar/creosote
Dazomet
Diiodomethyl p-tolyl sulfone (Amical 48)
Ethylene oxide (ETO) (TRED completed in FY 2006)
Formaldehyde
Grotan
Inorganic thiosulfates (ammonium thiosulfate)
Methyl bromide (soil fumigant uses; commodity uses TRED & RED completed FY 2006)
Methyldithiocarbamate salts (metam sodium/metam potassium)
MITC (methyl isothiocyanate)
Naphthalene
Nicotine
Organic esters of phosphoric acid
Pentachlorophenol
Prometon
Siduron
Sodium fluoride
Sulfometuron methyl
Sumithrin
Tetramethrin
Tributyltin-containing compounds
Triclosan (Irgasan)
Triforine

H. Projected Year of Completion of Reregistrations

EPA expects to complete 27 remaining reregistration eligibility decisions in FY 2008. Product reregistration, which takes place only after the reregistration eligibility decisions have been completed for the active ingredients, will not likely be completed before 2014.

List of Subjects

Environmental protection, Pesticides and pests.

Dated: August 22, 2008.

James B. Gulliford,

Assistant Administrator, Office of Prevention, Pesticides and Toxic Substances.

[FR Doc. E8–20236 Filed 9–2–08; 8:45 am]

BILLING CODE 6560–50–S

FARM CREDIT SYSTEM INSURANCE CORPORATION

Farm Credit System Insurance Corporation Board; Regular Meeting

SUMMARY: Notice is hereby given of the regular meeting of the Farm Credit System Insurance Corporation Board (Board).

Date and Time: The meeting of the Board will be held at the offices of the Farm Credit Administration in McLean, Virginia, on September 11, 2008, from 10 a.m. until such time as the Board concludes its business.

FOR FURTHER INFORMATION CONTACT: Roland E. Smith, Secretary to the Farm Credit System Insurance Corporation Board, (703) 883–4009, TTY (703) 883–4056.

ADDRESSES: Farm Credit System Insurance Corporation, 1501 Farm Credit Drive, McLean, Virginia 22102.

SUPPLEMENTARY INFORMATION: Parts of this meeting of the Board will be open to the public (limited space available) and parts will be closed to the public. In order to increase the accessibility to Board meetings, persons requiring assistance should make arrangements in advance. The matters to be considered at the meeting are:

Open Session

A. Approval of Minutes

- June 12, 2008

B. Business Reports

- June 30, 2008 Financial Report
- Report on Insured and Other Obligations
- Quarterly Report on Annual Performance Plan

C. New Business

- Annual Performance Plan FY 2009–2010
- Proposed 2009 and 2010 Budgets
- Insurance Fund Progress Review and Setting of Premium Range Guidance for 2009

Closed Session

- Report on System Performance

Dated: August 27, 2008.

Roland E. Smith,

Secretary, Farm Credit System Insurance Corporation Board.

[FR Doc. E8–20380 Filed 9–2–08; 8:45 am]

BILLING CODE 6710–01–P

FEDERAL TRADE COMMISSION

Public Workshops and Roundtables: Emerging Health Care Competition and Consumer Issues

AGENCY: Federal Trade Commission

ACTION: Notice of Public Workshops and Roundtables and Opportunity for Comment

SUMMARY: The Federal Trade Commission (''FTC'' or ''Commission'') announces it will hold two workshops and roundtables in the fall of 2008 on emerging health care competition and consumer issues. They will focus on two distinct areas in which competition and consumer protection policies are implicated: (1) competition provided by developing an abbreviated regulatory approval pathway for follow-on biologic drugs; and (2) competition among health care providers based on quality information. The workshops and roundtables will be held at and administered by the FTC and their dates will be announced in a separate public notice.

This notice poses a series of questions for which the FTC seeks public comment. The Commission will consider these comments as it prepares for the public workshops and roundtables. In the spring of 2009, the FTC will release a report that analyzes the potential impacts on the marketplace of various policy options in these two areas.

DATES: Specific dates for the workshops and roundtables will be announced shortly, along with an agenda. Comments on the questions contained in this Notice must be received on or before September 30, 2008. In addition, any interested person may submit written comments to any of the topics addressed during the workshops. Comments directed at a particular subject considered in a workshop or roundtable must be received no later than 30 days after the date of that workshop or roundtable.

ADDRESSES: Interested parties are invited to submit written comments electronically or in paper form. Comments should refer to ''Emerging Health Care Competition and Consumer Issues—Comment, Project No. P083901'' to facilitate the organization of the comments. Comments containing material for which confidential treatment is requested must be filed in paper form, must be clearly labeled ''Confidential,'' and must comply with Commission Rule 4.9(c).[1] Comments should not include any sensitive personal information, such as an individual's Social Security Number; date of birth; driver's license number or other state identification number or foreign country equivalent; passport number; financial account number; or credit or debit card number. Comments also should not include any sensitive health information, such as medical records and other individually identifiable health information.

Because paper mail in the Washington area, and specifically to the FTC, is subject to delay due to heightened security screening, please consider submitting your comments in electronic form. Comments filed in electronic form should be submitted by using the following weblink: (*http://secure.commentworks.com/ftc-healthcarecompetition*) and following the instructions on the web-based form. If this Notice appears at *http://www.regulations.gov,* you may also file an electronic comment through that website. The Commission will consider all comments that regulations.gov forwards to it.

A comment filed in paper form should include the ''Emerging Health Care Competition and Consumer Issues—Comment, Project No. P083901'' reference both in the text and on the envelope, and should be mailed or delivered to the following address: Federal Trade Commission, Office of the Secretary, Room H-135 (Annex F), 600 Pennsylvania Avenue, NW, Washington, DC 20580.

The Federal Trade Commission Act (''FTC Act'') and other laws the Commission administers permit the collection of public comments to consider and use in this proceeding as appropriate. The Commission will consider all timely and responsive public comments that it receives, whether filed in paper or electronic form. Comments received will be available to the public on the FTC website, to the extent practicable, at (*http://www.ftc.gov/os/publiccomments.htm.*) As a matter of discretion, the Commission makes every effort to remove home contact information for individuals from the public comments it receives before placing those comments on the FTC website. More information, including routine uses permitted by the Privacy Act, may be found in the FTC's privacy policy, at *www.ftc.gov/ftc/privacy.shtmwww.ftc.gov.*

FOR FURTHER INFORMATION CONTACT: Michael Wroblewski, Bureau of Competition, 600 Pennsylvania Avenue, N.W., Washington, D.C. 20580; telephone (202) 326-2435; e-mail: *mwroblewski@ftc.gov.* Detailed agendas for the workshop will be available on the FTC Home Page (*http://www.ftc.gov*).

SUPPLEMENTARY INFORMATION: Issues arising from the application of competition and consumer protection law to health care have tremendous significance for the U.S. economy and consumer/patient welfare. The 2004 Federal Trade Commission and Department of Justice Report, ''Improving Health Care: A Dose of Competition'' described the economic significance of health care to U.S. productivity. It has become even more so in the intervening four years. The Commission has an important role to play in health care markets through its missions of maintaining competition and protecting consumers.

The Commission intends to focus on two emerging areas that implicate both its competition and consumer protection mission: (1) competition provided by developing an abbreviated regulatory approval pathway for follow-on biologic drugs;[2] and (2) competition

[1] The comment must be accompanied by an explicit request for confidential treatment, including the factual and legal basis for the request, and must identify the specific portions of the comment to be withheld from the public record. The request will be granted or denied by the Commission's General Counsel, consistent with applicable law and the public interest. *See* Commission Rule 4.9(c), 16 CFR 4.9(c).

[2] Follow-on biologic drugs refer to those drugs that are sufficiently similar to an approved or

Continued